Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Limited announced that Berjis Desai will step down as Chairman and Director due to his appointment to the National Commission for Minorities, effective after the company's Annual General Meeting. Simultaneously, the company appointed Raghu Kumar as an Additional Director (Non-Executive and Independent), effective August 6, 2026, and named Satish Mehta, currently Managing Director & CEO, as the new Chairman, also effective after the AGM.

Emcure Pharmaceuticals Limited will hold its 45th Annual General Meeting on September 21, 2026, to approve a final dividend of Rs 3.60 per equity share, representing 36%, for the financial year ended March 31, 2026, with a record date of September 4, 2026.

Emcure Pharmaceuticals Ltd share price slipped 0.91% to Rs 1959.1. The Company's net profit saw a strong growth of 20% to Rs 292.49 crore, while revenue from operations slightly gained 4.48% to Rs 2580.45 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.84 lakh crore, easing 5.15%. It has inched up 1.03% over last one week and advanced by 11.63% in last one month while the market capitalization of Emcure Pharmaceuticals Ltd has improved by 2.57% and 19.40% in the same period respectively. Profit before tax (PBT) of Emcure Pharmaceuticals Ltd stood at Rs 393.53 crore in Q2 FY26, jumping 35.35% year-on-year, and rallying 15.34% quarter-on-quarter. EBITDA came in at Rs 530 crore, expanding by 28.41% YoY and rising by 11.54% sequentially. Total expenses grew marginally by 2.91% to Rs 2157.46 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 481.14 crore, rising 14.95% YoY, while employee benefits expense was at Rs 409.5 crore, inching up 5.87% YoY. For the TTM ended FY26, revenue from operations grew 18.59% to Rs 7896.0 crore, while net profit jumped 34.10% to Rs 707.47 crore, compared to previous TTM. EBITDA surged by 124346% to Rs 1407.12 crore, and PBT witnessed a strong rise of 33.57% to Rs 971.35 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 851.71 crore in FY26, as against Rs 1097.24 crore in FY25. Emcure Pharmaceuticals Ltd rallied 36.57% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.64% during the same period.

Emcure Pharmaceuticals announced that it has completed the acquisition of 663,865 equity shares constituting 12.05% of balance equity share capital of Gennova Biopharmaceuticals (Gennova) for an aggregate consideration of Rs231.87 crore. With this acquisition, Gennova has become a wholly owned subsidiary of the company.

Emcure Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 6 August 2026.

For FY2025-26, the revenue and the networth of the mRNA business of Gennova Biopharmaceuticals were Rs 64.71 crore (0.71% of consolidated revenue of Emcure Pharma) and Rs 132.63 crore (2.68% of consolidated net worth of Emcure Pharma), respectively. The mRNA business business has been divested for a total cash consideration of Rs 139.5 crore. Emcure Pharma expects the transaction to be completed by 17 July 2026. The company stated that the transfer of mRNA business is part of Gennova's strategic initiative to reorganize its business operations and focus on core areas, which are research and development, manufacturing and marketing of biotechnology-based products including biosimilars and adjacent therapeutic platforms. Pune-based Emcure Pharmaceuticals develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Emcure is present in 70+ countries globally, including Europe and Canada. On a consolidated basis, Emcure Pharmaceuticals' net profit rose 28.81% to Rs 243.40 crore while net sales rose 16.70% to Rs 2469.70 crore in Q4 March 2026 over Q4 March 2025. The scrip rose 0.15% to end at Rs 1810.45 on the BSE on Friday. Powered by Capital Market - Live

Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals, has executed a Business Transfer Agreement for transfer of its mRNA business as a going concern on a slump sale basis for a cash consideration of Rs 139.5 crore to Immunoscript Life Science on 10 July'2026. The transfer of mRNA business is part of Gennova's strategic initiative to reorganize its business operations and focus on core areas - research and development, manufacturing and marketing of biotechnology based products including biosimilars and adjacent therapeutic platforms.

Emcure Pharmaceuticals announced that Marcan Pharmaceuticals Inc., a subsidiary of the Company (Marcan) has on 02 July 2026 (EDT) entered into share purchase agreements with certain shareholders of Mantra Pharma Inc., a step-down subsidiary of the Company (Mantra), to acquire all of Class E Special Shares in the share capital of Mantra for an aggregate consideration of CAD $ 50 million. Consequently, Mantra continues to be 100% subsidiary of Marcan. Mantra Pharma Inc., a company incorporated under the laws of Quebec, Canada, is engaged in the marketing and distribution of prescription drugs and natural health products.

The revised target price implies a potential upside of about 11.6% from the current market price. The brokerage remains optimistic on Emcure's growth prospects and expects the company to deliver low- to mid-teen revenue growth in FY27. It also forecasts EBITDA margin expansion of 75-100 basis points during the year. According to the brokerage, margin improvement is likely to be driven by higher productivity of the company's field force in India and new product launches across key international markets. The brokerage highlighted Emcure's focus on research and development-backed products as a key pillar of its long-term growth strategy. Reflecting its improved outlook, the brokerage raised its earnings per share (EPS) estimates by 1-5% and expects the company to deliver an EPS compound annual growth rate (CAGR) of around 20% over FY26-FY29. Pune-based Emcure Pharmaceuticals develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Emcure is present in 70+ countries globally, including Europe and Canada. On a consolidated basis, Emcure Pharmaceuticals' net profit rose 28.81% to Rs 243.40 crore while net sales rose 16.70% to Rs 2469.70 crore in Q4 March 2026 over Q4 March 2025. Powered by Capital Market - Live

Emcure Pharmaceuticals has allotted 26,000 equity shares under ESOS on 19 June 2026. With this allotment, the paid up equity share capital has increased to 18,96,80,147 equity shares of Rs. 10/- each aggregating to Rs. 1,89,68,01,470/-.